Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

1(16.7%)

Phase 3

1(16.7%)

6Total

Phase 1(4)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06263478Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

Role: lead

NCT04661007Phase 1Active Not Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Role: lead

NCT04674748Phase 1Terminated

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

Role: lead

NCT04434937Phase 2Completed

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

Role: lead

NCT05068466Phase 1Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707

Role: lead

NCT03910530Phase 1Completed

A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

Role: lead

All 6 trials loaded